Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone - PubMed
4 hours ago
- #real-world outcomes
- #multiple myeloma
- #daratumumab
- Study focuses on real-world outcomes of newly diagnosed multiple myeloma patients.
- Patients were treated with front-line daratumumab, bortezomib, lenalidomide, and dexamethasone.
- PMID: 41784017 and DOI: 10.3324/haematol.2025.300401 provided for reference.
- Abstract details not available in the provided text.